Deucravacitinib for vitiligo

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Mar 2024: Trial registered, NCT06327321
  2. 5 May 2024: Trial started, NCT06327321

The trials

NCT06327321: Vitiligo Treatment by Targeting TYK2 Mediated Responses

State
Under way
Phase
Phase 2
People
128 planned
Started
5 May 2024
Primary completion
5 Nov 2026
Arms
Drug group
Results
None posted
  1. 25 Mar 2024: Trial registered
  2. 5 May 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Sotyktu.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.